Skip to main content
SpringerLink
Log in

Atovaquone oral suspension USP 750 mg/5mL: recall due to microbial contamination

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • US Food & Drug Administration (FDA). AvKARE, LLC. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750 mg/5 mL Due to Potential Bacillus Cereus Contamination. Internet Document : 1 Apr 2024. Available from: URL: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/avkare-llc-issues-voluntary-nationwide-recall-atovaquone-oral-suspension-usp-750-mg5-ml-due

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Atovaquone oral suspension USP 750 mg/5mL: recall due to microbial contamination. Reactions Weekly 2004, 3 (2024). https://doi.org/10.1007/s40278-024-56642-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-024-56642-5

Search

Navigation